Y-Biologics CEO Youngwoo Park Increases Stake Through On-Market Share Purchases
The management of Y-Biologics, a company specializing in the development of multi-antibody novel drugs, has strengthened its commitment to responsible management by purchasing common shares of the company.
On July 1, Y-Biologics announced that CEO Youngwoo Park had acquired 18,000 shares of the company’s common stock through on-market purchases. The acquisition took place over eight separate transactions between June 1 and June 29. As a result, CEO Park’s ownership stake increased to 23.01%, and the combined stake held by the largest shareholders, including those with special relationships, rose to 30.4%.
Y-Biologics is focusing on the research and development of next-generation immuno-oncology therapeutics. The company is expanding its open innovation efforts by conducting joint research and technical exchanges with multiple domestic and international biotech firms. In particular, to accelerate the early out-licensing (L/O) of its pipeline, Y-Biologics is working to secure translational research data from patient-derived tissue samples in collaboration with major domestic hospitals and KAIST.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
CEO Park stated, "Going forward, we will continue to translate our proprietary technological capabilities into tangible results in both research and commercialization, and do our utmost to enhance both corporate value and shareholder value."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.